PRPO

Precipio, Inc.

7.21 USD

Last updated Nov 29, 11:46 UTC

Yesterday HIGH

$6.58

Yesterday LOW

$6.46

52w HIGH

$20.48

52w LOW

$4.75

EPS

-1.8

PE

-4.01

Next Earnings

Dec 12, 2023

Overview News Insider Transactions Government Trades

Precipio, Inc. stock is down -9.08% since 30 days ago. The next earnings date is Dec 12, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 9 November’s closed higher than October.

Precipio, Inc. provides diagnostic blood cancer testing services in the United States. The company sells ICE-COLD-PCR technology kits to bio-pharma customers. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Measuring And Control Equipment

Headquarters

Omaha, United States Of America

Website

precipiodx.com

Benzinga Insights

Thu Jun 8, 2023

12 Health Care Stocks Moving In Thursday's Intraday Session
Lisa Levin

Thu Jun 8, 2023

Why Oxford Industries Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers Baosheng Media Group Holdings Limited (NASDAQ: BAOS) shares climbed 91.2% to $10.81.
Benzinga Insights

Thu Jun 8, 2023

Stocks That Hit 52-Week Lows On Thursday

During Thursday, 35 stocks hit new 52-week lows.
Lisa Levin

Thu Jun 8, 2023

Nasdaq Surges Over 100 Points; Signet Jewelers Shares Tumble After Q1 Results

U.S. stocks traded higher midway through trading, with Nasdaq Composite gaining over 100 points on Thursday. The Dow traded up 0.21% to 33,735.90 while the NASDAQ rose 0.94% to 13,228.32. The S&P 500, also rose, gaining, 0.42% to 4,285.24.
Benzinga Insights

Thu Jun 8, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Happy Mohamed

Thu Jun 8, 2023

Precipio, Inc. Announces Pricing Of $2M Registered Direct Offering And Concurrent Private Placement

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,125,000
Benzinga Newsdesk

Wed Jun 7, 2023

Precipio, Inc. Projected Cash Burn Reduced By $1.5M Annually From Three Operational Efficiency Projects

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that several operational improvement initiatives which commenced at the start of the year have begun to impact the cash burn and
Benzinga Newsdesk

Mon May 22, 2023

Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression Of p190 & p210 Isoforms In A CML Patient By Using HemeScreen Technology

Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210
Happy Mohamed

Thu May 4, 2023

Precipio Signs Another HemeScreen Customer

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additional
Benzinga Newsdesk

Fri Apr 28, 2023

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum